We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
Read MoreHide Full Article
Nektar (NKTR - Free Report) announced a partnership with Cellular Biomedicine to develop its pipeline candidate, NKTR-255, as a combination therapy for advanced non-small cell lung cancer (NSCLC) patients who are relapsed or refractory to anti-PD-1 therapy.
The early-stage study will evaluate NKTR-255, a novel IL-15 receptor agonist, in combination with Cellular Biomedicine’s C-TIL051 — a tumor-infiltrating lymphocyte (TIL) therapy for the same indication.
Per the collaboration, Cellular Biomedicine will add NKTR-255 to its ongoing phase I study of C-TIL05 in patients with NSCLC who are relapsed or refractory to anti-PD-1 therapy. Both Nektar and Cellular Biomedicine will maintain the existing global rights to their respective investigational candidates.
NKTR-255 is being evaluated in two separate mid-stage studies, in combination with cell therapies and immunotherapy. In preclinical and earlier clinical studies, NKTR-255 showed improvements in proliferation and persistence of cellular therapies, including TIL, TCR and CAR-T to increase specific anti-tumor activity.
Nektar was looking for strategic partnership options for NKTR-255’s development. The collaboration with Cellular Biomedicine aligns perfectly with NKTR’s strategic plans.
The company’s shares have lost 73.3% year to date compared with the industry's 7.9% decline.
Image Source: Zacks Investment Research
Nektar’s another pipeline candidate, rezpegaldesleukin (rezpeg), is being developed in an early-stage study for patients suffering from moderate-to-severe atopic dermatitis (AD), also known as eczema.
Earlier this month, shares of the company were up on positive new data for phase Ib study of rezpeg in AD. Data from the study showed that treatment with rezpeg led to a statistically significant improvement in clinical efficiency endpoints as measured by Body Surface Area, Dermatology Life Quality Index and Patient-Oriented Eczema Measure.
Nektar regained full rights to rezpeg from Eli Lily (LLY - Free Report) in April 2023, and is now in-charge of its clinical development. Rezpeg is a wholly owned asset of Nektar, and the company owes no royalty payments to LLY.
Rezpeg was earlier developed in collaboration with Eli Lilly for several autoimmune indications. However, in February, LLY announced that the phase II study evaluating rezpeg for systemic lupus erythematosus (SLE) did not meet the primary endpoint of a reduction in SLE disease activity index at six months. LLY and Nektar were also co-developing the candidate for AD. Following the above setback, Eli Lilly notified Nektar that it did not intend to advance rezpeg for SLE treatment.
In the past 90 days, the Zacks Consensus Estimate forAnika Therapeutics has narrowed from a loss of $1.41 per share to a loss of $1.24 for 2023. The bottom-line estimate has widened from a loss of 79 cents to a loss of 82 cents for 2024 during the same time frame. Shares of the company have lost 37.5% year to date.
ANIK’s earnings beat estimates in one of the trailing four quarters and missed the mark in the remaining three, delivering an average negative surprise of 32.12%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to a loss of $2.77 for 2024 during the same time frame. Shares of the company have lost 28.8% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
Nektar (NKTR - Free Report) announced a partnership with Cellular Biomedicine to develop its pipeline candidate, NKTR-255, as a combination therapy for advanced non-small cell lung cancer (NSCLC) patients who are relapsed or refractory to anti-PD-1 therapy.
The early-stage study will evaluate NKTR-255, a novel IL-15 receptor agonist, in combination with Cellular Biomedicine’s C-TIL051 — a tumor-infiltrating lymphocyte (TIL) therapy for the same indication.
Per the collaboration, Cellular Biomedicine will add NKTR-255 to its ongoing phase I study of C-TIL05 in patients with NSCLC who are relapsed or refractory to anti-PD-1 therapy. Both Nektar and Cellular Biomedicine will maintain the existing global rights to their respective investigational candidates.
NKTR-255 is being evaluated in two separate mid-stage studies, in combination with cell therapies and immunotherapy. In preclinical and earlier clinical studies, NKTR-255 showed improvements in proliferation and persistence of cellular therapies, including TIL, TCR and CAR-T to increase specific anti-tumor activity.
Nektar was looking for strategic partnership options for NKTR-255’s development. The collaboration with Cellular Biomedicine aligns perfectly with NKTR’s strategic plans.
The company’s shares have lost 73.3% year to date compared with the industry's 7.9% decline.
Image Source: Zacks Investment Research
Nektar’s another pipeline candidate, rezpegaldesleukin (rezpeg), is being developed in an early-stage study for patients suffering from moderate-to-severe atopic dermatitis (AD), also known as eczema.
Earlier this month, shares of the company were up on positive new data for phase Ib study of rezpeg in AD. Data from the study showed that treatment with rezpeg led to a statistically significant improvement in clinical efficiency endpoints as measured by Body Surface Area, Dermatology Life Quality Index and Patient-Oriented Eczema Measure.
Nektar regained full rights to rezpeg from Eli Lily (LLY - Free Report) in April 2023, and is now in-charge of its clinical development. Rezpeg is a wholly owned asset of Nektar, and the company owes no royalty payments to LLY.
Rezpeg was earlier developed in collaboration with Eli Lilly for several autoimmune indications. However, in February, LLY announced that the phase II study evaluating rezpeg for systemic lupus erythematosus (SLE) did not meet the primary endpoint of a reduction in SLE disease activity index at six months. LLY and Nektar were also co-developing the candidate for AD. Following the above setback, Eli Lilly notified Nektar that it did not intend to advance rezpeg for SLE treatment.
Nektar Therapeutics Price and Consensus
Nektar Therapeutics price-consensus-chart | Nektar Therapeutics Quote
Zacks Rank & Stocks to Consider
Nektar currently carries a Zacks Rank #3 (Buy).
A couple of better-ranked stocks in the same industry are Anika Therapeutics (ANIK - Free Report) and Annovis Bio (ANVS - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate forAnika Therapeutics has narrowed from a loss of $1.41 per share to a loss of $1.24 for 2023. The bottom-line estimate has widened from a loss of 79 cents to a loss of 82 cents for 2024 during the same time frame. Shares of the company have lost 37.5% year to date.
ANIK’s earnings beat estimates in one of the trailing four quarters and missed the mark in the remaining three, delivering an average negative surprise of 32.12%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to a loss of $2.77 for 2024 during the same time frame. Shares of the company have lost 28.8% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.